[go: up one dir, main page]

MA35873B1 - Variants polypeptidiques du récepteur de l'activine, seuls ou en combinaison avec une chimiothérapie, et leurs utilisations - Google Patents

Variants polypeptidiques du récepteur de l'activine, seuls ou en combinaison avec une chimiothérapie, et leurs utilisations

Info

Publication number
MA35873B1
MA35873B1 MA37223A MA37223A MA35873B1 MA 35873 B1 MA35873 B1 MA 35873B1 MA 37223 A MA37223 A MA 37223A MA 37223 A MA37223 A MA 37223A MA 35873 B1 MA35873 B1 MA 35873B1
Authority
MA
Morocco
Prior art keywords
chemotherapy
alone
combination
activin receptor
polypeptide variants
Prior art date
Application number
MA37223A
Other languages
English (en)
Inventor
Lei-Ting Tony Tam
Xiaolan Zhou
Jeonghoon Sun
Huiquan Han
Keith Soo-Nyung Kwak
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/329,897 external-priority patent/US8501678B2/en
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA35873B1 publication Critical patent/MA35873B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des variants polypeptidiques du récepteur soluble iib de l'activine et des protéines aptes à se lier et d'inhiber les activités de l'activine a, de la myostatine ou de gdf-11. La présente invention concerne également des polynucléotides, des vecteurs et des cellules-hôtes aptes à produire les variants polypeptidiques et protéiques. L'invention concerne également des compositions et des méthodes de traitement de maladies et de troubles de dégradation musculaire et d'autres maladies et troubles.
MA37223A 2011-12-19 2014-07-18 Variants polypeptidiques du récepteur de l'activine, seuls ou en combinaison avec une chimiothérapie, et leurs utilisations MA35873B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/329,897 US8501678B2 (en) 2007-03-06 2011-12-19 Variant activin receptor polypeptides and uses thereof
PCT/US2012/070571 WO2013106175A1 (fr) 2011-12-19 2012-12-19 Variants polypeptidiques du récepteur de l'activine, seuls ou en combinaison avec une chimiothérapie, et leurs utilisations

Publications (1)

Publication Number Publication Date
MA35873B1 true MA35873B1 (fr) 2014-12-01

Family

ID=47501527

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37223A MA35873B1 (fr) 2011-12-19 2014-07-18 Variants polypeptidiques du récepteur de l'activine, seuls ou en combinaison avec une chimiothérapie, et leurs utilisations

Country Status (21)

Country Link
US (1) US9610327B2 (fr)
EP (1) EP2793925B1 (fr)
JP (3) JP6145112B2 (fr)
KR (1) KR20140108562A (fr)
CN (1) CN104379159A (fr)
AU (2) AU2012364736A1 (fr)
BR (1) BR112014015003A2 (fr)
CA (1) CA2859504A1 (fr)
CL (1) CL2014001648A1 (fr)
CO (1) CO7101190A2 (fr)
CR (1) CR20140304A (fr)
EA (1) EA201491231A8 (fr)
HK (1) HK1203384A1 (fr)
IL (1) IL233178A0 (fr)
MA (1) MA35873B1 (fr)
MX (1) MX358358B (fr)
PE (1) PE20142114A1 (fr)
PH (1) PH12014501385A1 (fr)
SG (2) SG10201605027XA (fr)
TN (1) TN2014000270A1 (fr)
WO (1) WO2013106175A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160137665A (ko) 2005-11-23 2016-11-30 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒⅱａ 길항제 및 골 성장을 촉진하기 위한 이들의 용도
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
JP5237970B2 (ja) 2007-02-01 2013-07-17 アクセルロン ファーマ， インコーポレイテッド 乳癌を治療または予防するためのアクチビンＡｃｔＲＩＩａアンタゴニストおよび使用
TW201803890A (zh) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
JP5574711B2 (ja) 2007-02-09 2014-08-20 アクセルロン ファーマ， インコーポレイテッド 癌患者における骨成長を促進するためのアクチビン−ａｃｔｒｉｉａアンタゴニストおよびその使用
TW201718635A (zh) 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
US7960343B2 (en) 2007-09-18 2011-06-14 Acceleron Pharma Inc. Activin-ActRIIa antagonists and uses for decreasing or inhibiting FSH secretion
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
SI3750552T1 (sl) 2008-08-14 2023-10-30 Acceleron Pharma Inc. GDF pasti
WO2010151426A1 (fr) 2009-06-12 2010-12-29 Acceleron Pharma Inc. Protéines de fusion actriib-fc tronquées
CA2781152A1 (fr) 2009-11-17 2011-05-26 Acceleron Pharma Inc. Proteines actriib et variants et utilisations de celles-ci se rapportant a l'induction de l'utrophine pour une therapie de la dystrophie musculaire
SG187867A1 (en) 2010-08-16 2013-03-28 Amgen Inc Antibodies that bind myostatin, compositions and methods
KR20130132824A (ko) 2010-11-08 2013-12-05 악셀레론 파마 인코포레이티드 Actriia 결합제 및 이의 용도
MX358358B (es) 2011-12-19 2018-08-15 Amgen Inc Polipeptidos de receptores de activina variantes y sus usos.
EA201492282A1 (ru) 2012-06-11 2015-07-30 Амген Инк. Антагонистические антигенсвязывающие белки к двум рецепторам и их применение
NZ707477A (en) 2012-11-02 2019-09-27 Celgene Corp Activin-actrii antagonists and uses for treating bone and other disorders
CN105431455A (zh) * 2013-02-01 2016-03-23 圣塔玛丽亚生物疗法公司 抗激活素a化合物对受试者的施用
WO2015161220A1 (fr) * 2014-04-18 2015-10-22 Acceleron Pharma, Inc. Procédés d'augmentation des taux de globules rouges et de traitement de la drépanocytose
MA40008A (fr) 2014-06-13 2021-05-05 Acceleron Pharma Inc Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie
WO2016161477A1 (fr) * 2015-04-07 2016-10-13 Prince Henry's Institute Of Medical Research (Acn 132 025 024) Méthode de traitement de néoplasies
CA2983440C (fr) * 2015-04-22 2024-03-12 Alivegen Usa Inc. Nouvelles proteines hybrides piegeant le ligand actriib pour le traitement de maladies amyotrophiques
KR102764084B1 (ko) * 2015-11-11 2025-02-07 노파르티스 아게 미오스타틴 길항제의 용도, 이들을 함유하는 조합물 및 그의 용도
CN116284392A (zh) 2016-03-10 2023-06-23 艾科赛扬制药股份有限公司 活化素2型受体结合蛋白及其用途
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
JP7139326B2 (ja) 2016-11-10 2022-09-20 ケロス セラピューティクス インコーポレイテッド アクチビンＩＩａ型受容体変異体および同変異体を含む医薬組成物
US11484573B2 (en) 2017-11-09 2022-11-01 Keros Therapeutics, Inc. Activin receptor type IIa variants and methods of use thereof
IL275936B2 (en) 2018-01-12 2025-09-01 Keros Therapeutics Inc Activin receptor type iib variants and methods of using them
EP3790572A4 (fr) 2018-05-09 2022-03-16 Keros Therapeutics, Inc. Variants du récepteur de l'activine de type iia et leurs procédés d'utilisation
CA3176735A1 (fr) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Chimeres de type ii du recepteur d'activine et leurs methodes d'utilisation
EP4121088A4 (fr) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Procédés d'utilisation de variants de récepteur de l'activine de type iib

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5750375A (en) 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US6162896A (en) 1991-05-10 2000-12-19 The Salk Institute For Biological Studies Recombinant vertebrate activin receptors
US20050186593A1 (en) 1991-05-10 2005-08-25 The Salk Institute For Biological Studies Cloning and recombinant production of CRF receptor(s)
US5885794A (en) 1991-05-10 1999-03-23 The Salk Institute For Biological Studies Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily
WO1993015722A1 (fr) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Liberation controlee de produits pharmaceutiques a partir de microparticules poreuses preformees
US6153407A (en) 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
DE69232604T2 (de) 1992-11-04 2002-11-07 City Of Hope Duarte Antikörperkonstrukte
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US5827733A (en) 1993-03-19 1998-10-27 The Johns Hopkins University School Of Medicine Growth differentiation factor-8 (GDF-8) and polynucleotides encoding same
US6607884B1 (en) 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
US6465239B1 (en) 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
JPH10511840A (ja) 1994-04-29 1998-11-17 クリエイティブ バイオモレキュールズ，インコーポレイテッド 形態形成タンパク質特異細胞表面レセプターおよびその使用
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ATE362534T2 (de) 1998-11-13 2007-06-15 Immunex Corp Menschliche tslp nukleinsäuren und polypeptide
EP1147413B1 (fr) 1999-01-21 2006-04-05 Metamorphix, Inc. Inhibiteurs de facteurs de differenciation de la croissance et leurs utilisations
JP4487376B2 (ja) 2000-03-31 2010-06-23 味の素株式会社 腎疾患治療剤
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
CA2453986A1 (fr) 2001-07-18 2003-01-30 Merck Patent Gesellschaft Mit Beschraenkter Haftung Proteine de fusion, glycoproteine vi
GB0209896D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
EA009056B1 (ru) 2002-12-20 2007-10-26 Амген, Инк. Связывающие агенты, ингибирующие миостатин
PT2821067T (pt) * 2003-09-12 2017-12-01 Amgen Inc Formulação de cinacalcet de dissolução rápida
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
EP1682582B1 (fr) 2003-11-13 2011-08-31 Hanmi Holdings Co., Ltd Methode de production en masse d'une region constante des immunoglobulines
SI1750683T1 (sl) * 2004-04-23 2013-04-30 Amgen Inc. M/S 27-4-A, Amgen Inc. Formulacije s podaljĺ anim sproĺ äśanjem
ES2551852T3 (es) 2004-07-23 2015-11-24 Acceleron Pharma Inc. Polipéptidos del receptor ActRII
US20060034831A1 (en) 2004-08-12 2006-02-16 Wyeth Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors
ES2629397T3 (es) 2004-09-24 2017-08-09 Amgen Inc. Moléculas de Fc modificadas
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
EP1933871B1 (fr) 2005-09-07 2013-04-24 Amgen Fremont Inc. Anticorps monoclonaux humains dirigés contre la kinase-1 de la famille du récepteur d'activine (alk-1)
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
TW201803890A (zh) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
TW201718635A (zh) * 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
ES2449753T3 (es) 2007-03-19 2014-03-21 National Research Council Of Canada Proteínas de fusión que comprenden dos dominios de unión tgf-beta
US7960343B2 (en) 2007-09-18 2011-06-14 Acceleron Pharma Inc. Activin-ActRIIa antagonists and uses for decreasing or inhibiting FSH secretion
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
SI3750552T1 (sl) 2008-08-14 2023-10-30 Acceleron Pharma Inc. GDF pasti
PT2370463T (pt) * 2008-11-26 2016-11-04 Amgen Inc Variante estabilizada do receptor da activina iib
US8138142B2 (en) 2009-01-13 2012-03-20 Acceleron Pharma Inc. Methods for increasing adiponectin in a patient in need thereof
EP3845239A1 (fr) 2009-06-08 2021-07-07 Acceleron Pharma Inc. Utilisation de protéines anti-actriib pour l'augmentation d'adipocytes thermogènes
EP3919068A1 (fr) 2009-09-09 2021-12-08 Acceleron Pharma Inc. Antagonistes d'actriib, et dosage et administration associés pour promouvoir la formation de globules rouges
WO2011085165A2 (fr) 2010-01-08 2011-07-14 The Brigham And Women's Hospital, Inc. Complexes immuns du ca-125 en tant que biomarqueurs du cancer ovarien
MX2011011596A (es) 2010-03-31 2012-02-01 Keryx Biopharmaceuticals Inc Perifosina y capecitabina como un tratamiento combinado para cancer.
KR20130132824A (ko) 2010-11-08 2013-12-05 악셀레론 파마 인코포레이티드 Actriia 결합제 및 이의 용도
MX358358B (es) 2011-12-19 2018-08-15 Amgen Inc Polipeptidos de receptores de activina variantes y sus usos.
EP2802308A1 (fr) 2012-01-13 2014-11-19 Allergan, Inc. Gels de collagène et d'acide hyaluronique réticulés destinés à améliorer la viabilité d'une greffe de tissu et l'augmentation de tissu mou

Also Published As

Publication number Publication date
CL2014001648A1 (es) 2015-01-09
IL233178A0 (en) 2014-07-31
JP6145112B2 (ja) 2017-06-07
CA2859504A1 (fr) 2013-07-18
MX358358B (es) 2018-08-15
BR112014015003A2 (pt) 2019-09-24
WO2013106175A1 (fr) 2013-07-18
PE20142114A1 (es) 2015-01-04
NZ626580A (en) 2016-07-29
MX2014007483A (es) 2014-09-12
AU2012364736A1 (en) 2014-07-24
EP2793925B1 (fr) 2019-03-20
KR20140108562A (ko) 2014-09-11
EA201491231A1 (ru) 2014-09-30
US9610327B2 (en) 2017-04-04
CO7101190A2 (es) 2014-10-31
JP2017178953A (ja) 2017-10-05
JP2015505859A (ja) 2015-02-26
SG10201605027XA (en) 2016-08-30
HK1203384A1 (en) 2015-12-11
CR20140304A (es) 2014-10-07
JP2018145198A (ja) 2018-09-20
AU2017248486B2 (en) 2019-10-03
AU2017248486A1 (en) 2017-11-09
CN104379159A (zh) 2015-02-25
EA201491231A8 (ru) 2015-01-30
SG11201403367YA (en) 2014-07-30
JP6542433B2 (ja) 2019-07-10
JP6358633B2 (ja) 2018-07-18
EP2793925A1 (fr) 2014-10-29
PH12014501385A1 (en) 2014-09-15
TN2014000270A1 (en) 2015-09-30
US20140348827A1 (en) 2014-11-27

Similar Documents

Publication Publication Date Title
MA35873B1 (fr) Variants polypeptidiques du récepteur de l&#39;activine, seuls ou en combinaison avec une chimiothérapie, et leurs utilisations
EA200901270A1 (ru) Стимуляция иммунной реакции катионными липидами
EA200970810A1 (ru) Модифицированные полипептиды рецептора активина и их применение
CY1119766T1 (el) Νεοι ρυθμιστες κινασης βενζοπυρανιου
EA201291098A1 (ru) Новые соединения 3,5-дизамещенного-3h-имидазо[4,5-b]пиридина и 3,5-дизамещенного -3h-[1,2,3]триазоло[4,5-b]пиридина как модуляторы протеинкиназ
MX2019009255A (es) Proteínas quiméricas dirigidas y sus usos.
MA37975B2 (fr) Inhibiteurs de synthase de glucosylcéramide
EA201170624A1 (ru) Изоникотинамидные антагонисты рецепторов орексинов
UA107921C2 (en) Variants of polypeptide of receptor ivr activin and their use
EA201591176A1 (ru) Композиции и способы с использованием пептидной метки, связывающейся с гиалуронаном
MX2015006548A (es) Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2.
MA38183A1 (fr) Composés pyrrolopyrimidines en tant qu&#39;inhibiteurs de kinase
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
MX355877B (es) Peptidos terapeuticos.
MY155621A (en) Axl antibodies
EA201590207A1 (ru) Композиции и способы регуляции car-т-клеток
BR112015017619A2 (pt) formulação líquida, uso de uma formulação, e, kit
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
IN2012DN02735A (fr)
PL1830881T3 (pl) Terapie skojarzone celowane na wiele receptorów Toll-podobnych i ich zastosowanie
WO2010009478A3 (fr) Compositions et procédés pour traiter des troubles associés à des animaux en surpoids
UA99339C2 (ru) Антитело, которое специфично связывает человеческий tyrp1
EA201590962A1 (ru) Новые соединения
PH12012502070A1 (en) Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders
PH12014502352A1 (en) Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition